LeonaBio, Inc. has filed Amendment No. 2 to its Form 8-K/A with the SEC, amending its previous report dated December 18, 2025. This amendment addresses the Sermonix Transaction, which the SEC staff indicated constituted the acquisition of a business under Regulation S-X. The company has received a waiver from the SEC regarding the requirement to provide financial statements for the Sermonix acquisition, which is a significant aspect of this filing. The amendment includes updates to the descriptions of the transaction and the associated financial implications, as well as the addition of the Sermonix License as Exhibit 2.1. Furthermore, the filing reflects a change in the company's name from Athira Pharma, Inc. to LeonaBio, Inc., aligning with its rebranding efforts. The company anticipates that the changes in operational scope and financial resources will enhance the execution of the ELAINE-3 Study, a pivotal clinical trial for its product development. The filing is part of the company's ongoing compliance with SEC regulations and aims to provide clarity to investors regarding its strategic direction and operational execution.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.